TC BioPharm Ltd (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TCBP Nasdaq 8731 https://tcbiopharm.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for TC BioPharm Ltd (ADR)

TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies - Apr 4th, 2024 12:30 pm
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process - Apr 2nd, 2024 12:30 pm
TCBP Adjourns General Meeting Until a Later Date - Mar 19th, 2024 12:30 pm
TCBP Announces Exercise of Series D Warrants For Cash - Mar 18th, 2024 12:30 pm
Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show" - Mar 1st, 2024 1:30 pm
/C O R R E C T I O N -- TC BioPharm/ - Feb 27th, 2024 10:15 pm
TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial - Feb 22nd, 2024 2:32 pm
TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe - Feb 15th, 2024 1:30 pm
TCBP Provides Shareholder Update and Highlights Upcoming Milestones - Feb 14th, 2024 1:30 pm
TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show' - Jan 29th, 2024 1:30 pm
TC BioPharm to Present at the Sequire Investor Summit - Jan 18th, 2024 1:30 pm
TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement - Jan 4th, 2024 1:30 pm
TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies - Jan 3rd, 2024 1:30 pm
TC BioPharm Announces Closing of $3.5 Million Public Offering - Dec 22nd, 2023 1:30 pm
TC BioPharm Announces Pricing of $3.5 Million Public Offering - Dec 19th, 2023 1:00 pm
TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D - Dec 18th, 2023 4:15 pm
TC BioPharm Announces Plan to Implement ADS Ratio Change - Dec 13th, 2023 11:30 am
TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug - Nov 28th, 2023 4:05 pm
TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia - Nov 27th, 2023 1:45 pm
TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results - Nov 14th, 2023 3:00 pm